CA
BIIB icon

Crewe Advisors’s Biogen BIIB Stock Holding History

Crewe Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8K Buy
37
+9
+32% +$1.72K ﹤0.01% 800
2026
Q1 		$5.13K Buy
28
+17
+155% +$3.13K ﹤0.01% 773
2025
Q4 		$1.94K Hold
11
– – ﹤0.01% 887
2025
Q3 		$1.54K Buy
+11
New +$1.49K ﹤0.01% 874
2024
Q4 		– Sell
-20
Closed -$3.88K – 662
2024
Q3 		$3.88K Hold
20
– – ﹤0.01% 595
2024
Q2 		$4.64K Hold
20
– – ﹤0.01% 813
2024
Q1 		$4.31K Buy
+20
New +$4.68K ﹤0.01% 756
2023
Q3 		– Sell
-2
Closed -$570 – 623
2023
Q2 		$570 Buy
+2
New +$595 ﹤0.01% 618
2022
Q4 		– Sell
-27
Closed -$7K – 1049
2022
Q3 		$7K Buy
27
+9
+50% +$1.91K ﹤0.01% 748
2022
Q2 		$4K Buy
+18
New +$3.68K ﹤0.01% 794

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Crewe Advisors's BIIB Position: Q2 2026 in Review

Crewe Advisors increased its Biogen (BIIB) stake by 32% in Q2 2026, buying an estimated $1.72K and bringing the position to 37 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #800.

Crewe Advisors first reported a position in BIIB in Q2 2022 and has held it in 10 quarters since. 1,041 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Crewe Advisors held 37 shares of Biogen worth $8K as of Q2 2026.
  • Crewe Advisors bought 9 Biogen shares in Q2 2026, an estimated $1.72K.
  • Biogen made up ﹤0.01% of Crewe Advisors's portfolio in Q2 2026, its #800 holding.
  • Crewe Advisors first reported a position in Biogen in Q2 2022 and has held it in 10 quarters since.
  • 1,041 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Crewe Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.